It’s time to beat cancer

Vigeo is a clinical-stage biopharmaceutical company developing novel therapeutics that can effectively treat multiple types of cancer and improve the lives of patients.

Find Out More

We are building a first-in-class drug discovery pipeline that reprograms the tumor immune microenvironment (TIME). We believe that by reprogramming the TIME, we can significantly improve cancer treatment outcomes.

OUR APPROACH

Vigeo is currently developing therapies that target the TIME by activating thrombospondin-1 (Tsp-1), a naturally occurring potent anti-tumorigenic protein, and one of the body’s own defenses against cancer. Tsp-1 has been shown to attack cancer cells and to prevent their spread through metastasis via CD36 and CD47 pathways.

Learn More

OUR <strong>APPROACH</strong>

Our clinical
trials

We are currently studying VT1021, a peptide therapeutic agent in clinical trials enrolling patients in pancreatic, ovarian, triple negative breast cancers, glioblastoma, and tumors with high amounts of CD36.

Working at
Vigeo

Find out more about a career at Vigeo

?>

Latest News

April 09, 2020

Vigeo Therapeutics Doses First Patients in Expansion Phase of its 1b/2 Study Investigating VT1021 in Patients with CD36 Expressing Cancers 

Read More »

March 17, 2020

Biotech Strategy Blog – Interview with Vigeo CEO and Co-Founder

Read More »

October 15, 2019

Vigeo Therapeutics to Present at the 2019 BIO Investor Forum

Read More »